OBJECTIVE: We examined breast cancer risk related to lifetime exposure to oral contraceptives (OCs) and hormone replacement therapy (HRT) in postmenopausal women. METHODS: The Women's Contraceptive and Reproductive Experiences (CARE) Study was a population-based case-control study that included 1847 postmenopausal women with incident invasive breast cancer, and 1932 control subjects, identified using random digit dialing. RESULTS: 45% of cases and 49% of controls used both OCs and HRT. OC users were not at increased risk regardless of subsequent HRT exposure. HRT users who had used OCs previously did not have a higher risk of breast cancer than women with no exposure to OCs. We observed a negative interaction (p-value: 0.032) of combined hormone replacement therapy (CHRT) and past OC use. The increase in risk with CHRT was stronger in women who had never used OCs in the past (odds ratio: 1.05; 95% confidence interval: 1.01-1.10 per year of exclusive CHRT use) than in women who had used OCs (odds ratio: 1.00; 95% confidence interval: 0.97-1.03). CONCLUSIONS: We found no indication that adverse effects of exposure to OCs or HRT appeared only in the presence of the other hormone or were exacerbated by exposure to the other hormone.
OBJECTIVE: We examined breast cancer risk related to lifetime exposure to oral contraceptives (OCs) and hormone replacement therapy (HRT) in postmenopausal women. METHODS: The Women's Contraceptive and Reproductive Experiences (CARE) Study was a population-based case-control study that included 1847 postmenopausal women with incident invasive breast cancer, and 1932 control subjects, identified using random digit dialing. RESULTS: 45% of cases and 49% of controls used both OCs and HRT. OC users were not at increased risk regardless of subsequent HRT exposure. HRT users who had used OCs previously did not have a higher risk of breast cancer than women with no exposure to OCs. We observed a negative interaction (p-value: 0.032) of combined hormone replacement therapy (CHRT) and past OC use. The increase in risk with CHRT was stronger in women who had never used OCs in the past (odds ratio: 1.05; 95% confidence interval: 1.01-1.10 per year of exclusive CHRT use) than in women who had used OCs (odds ratio: 1.00; 95% confidence interval: 0.97-1.03). CONCLUSIONS: We found no indication that adverse effects of exposure to OCs or HRT appeared only in the presence of the other hormone or were exacerbated by exposure to the other hormone.
Authors: Nicole M Gatto; Matthew P Longnecker; Michael F Press; Jane Sullivan-Halley; Roberta McKean-Cowdin; Leslie Bernstein Journal: Cancer Causes Control Date: 2007-02 Impact factor: 2.506
Authors: Louise A Brinton; Douglas Richesson; Michael F Leitzmann; Gretchen L Gierach; Arthur Schatzkin; Traci Mouw; Albert R Hollenbeck; James V Lacey Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254
Authors: Valerie McGuire; Patricia Hartge; Linda M Liao; Rashmi Sinha; Leslie Bernstein; Alison J Canchola; Garnet L Anderson; Marcia L Stefanick; Alice S Whittemore Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-04-12 Impact factor: 4.254
Authors: Huiyan Ma; Yaping Wang; Jane Sullivan-Halley; Linda Weiss; Polly A Marchbanks; Robert Spirtas; Giske Ursin; Ronald T Burkman; Michael S Simon; Kathleen E Malone; Brian L Strom; Jill A McDonald; Michael F Press; Leslie Bernstein Journal: Cancer Res Date: 2010-01-12 Impact factor: 12.701